Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded by StockNews.com to Sell Rating

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by investment analysts at StockNews.com to a “sell” rating in a report issued on Friday.

Other equities research analysts also recently issued research reports about the company. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, November 27th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Finally, Sanford C. Bernstein cut their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.70.

Arrowhead Pharmaceuticals Trading Down 0.3 %

Shares of ARWR stock opened at $19.45 on Friday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $39.83. The firm’s 50 day moving average price is $21.26 and its two-hundred day moving average price is $23.05. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -3.87 and a beta of 0.91.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This represents a 7.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $21.24, for a total value of $567,362.88. Following the sale, the chief executive officer now directly owns 3,688,335 shares in the company, valued at approximately $78,340,235.40. This trade represents a 0.72 % decrease in their position. The disclosure for this sale can be found here. 4.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Fifth Third Bancorp raised its position in shares of Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares in the last quarter. Values First Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals during the third quarter worth approximately $52,000. Meeder Asset Management Inc. lifted its position in Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Finally, nVerses Capital LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $96,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.